NGFR and melanoma: Our previous study indicates that vemurafenib (PLX4032, Zelboraf), an inhibitor of V600EBRAF, and trametinib, an inhibitor of MEK1/2 (GSK1120212, Mekinist), increase percentages of CD271 (NGFR)-positive melanoma cells (stem-like/neural crest-like phenotype) while reducing the percentages of Ki-67-positive cells (proliferative phenotype) [5].